WO2000066117A1 - Use of (2s)-1- [(2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h- indole-2-carbonyl] pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon - Google Patents

Use of (2s)-1- [(2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h- indole-2-carbonyl] pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon Download PDF

Info

Publication number
WO2000066117A1
WO2000066117A1 PCT/FR2000/001085 FR0001085W WO0066117A1 WO 2000066117 A1 WO2000066117 A1 WO 2000066117A1 FR 0001085 W FR0001085 W FR 0001085W WO 0066117 A1 WO0066117 A1 WO 0066117A1
Authority
WO
WIPO (PCT)
Prior art keywords
raynaud
phenomenon
carboxamide
indole
chlorophenyl
Prior art date
Application number
PCT/FR2000/001085
Other languages
French (fr)
Inventor
Rémi BROUARD
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Priority to AU43035/00A priority Critical patent/AU4303500A/en
Publication of WO2000066117A1 publication Critical patent/WO2000066117A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a new use of a selective antagonist of the V 1a receptors for arginine-vasopressin.
  • compound A hereinafter referred to as compound A, was described in the literature as a potent and selective antagonist of ⁇ a of arginine vasopressin in different species, particularly receptors ⁇ a human, (C. Serradeil-Le Gay fl al., J. Clin. Invest., 1993, 92, 224-231). It has only a weak affinity for V 2 receptors.
  • Compound A is the most potent selective human V 1a receptor antagonist known to date.
  • the effects of compound A on vasoconstriction in humans induced by injection of arginine-vasopressin have been described in the literature by R. Weber et al., Hypertension, 1997, 30 (5), 1121-1127.
  • compound A as well as its pharmaceutically acceptable solvates and / or hydrates, are useful in the treatment or prevention of Raynaud's phenomenon.
  • Raynaud's phenomenon includes Raynaud's disease (primary) and Raynaud's syndrome (secondary).
  • the subject of the present invention is the use of (2S) -1 - [(2R, 3S) -5-chloro-3- (2-chlorophenyl) -1 - (3,4- dimethoxybenzenesulfonyl) -3-hydroxy-2,3-dihydro-1 / - / - indole-2-carbonyl] pyrrolidine-2-carboxamide, its pharmaceutically acceptable solvates and / or hydrates, for the preparation of medicaments useful in the treatment or prevention of Raynaud's phenomenon.
  • the subject of the present invention is the use of (2S) -1-
  • the present invention relates to the use of (2S) -1 - [(2R, 3S) -5-chloro-3- (2-chlorophenyl) -1 - (3,4- dimethoxybenzenesulfonyl) -3 -hydroxy-2,3-dihydro-1H-indole-2-carbonyl] pyrrolidine-2-carboxamide, of its pharmaceutically acceptable solvates and / or hydrates, for the preparation of medicaments useful in the treatment or prevention of Raynaud's syndrome.
  • the subject of the present invention is a method of treatment or prevention of Raynaud's phenomenon by administration of an appropriate dose of compound A, of its pharmaceutically acceptable solvates and / or hydrates.
  • compound A and its pharmaceutically acceptable solvates and / or hydrates are generally administered in dosage units.
  • Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
  • the active ingredient alone or in combination with another active ingredient can be administered in unit form administration, mixed with conventional pharmaceutical carriers, animals and humans.
  • Suitable unit administration forms include oral forms such as tablets, capsules, powders, granules and oral solutions or suspensions, sublingual and oral administration forms, aerosols, topical administration forms, implants, subcutaneous, transdermal, intramuscular, intravenous, intranasal and rectal administration forms.
  • oral forms of administration are preferred.
  • the daily dosage of compound A is from 0.05 to 5 mg / kg, advantageously from 1 to 2.5 mg / kg, preferably from 2 to 2.5 mg / kg, to be administered in one or more times.
  • Compound A and its solvates and / or hydrates are generally formulated in dosage units containing from 2.5 to 1000 mg, advantageously from 2.5 to 500 mg, preferably from
  • the appropriate dosage for each patient is determined by the doctor according to the mode of administration, the age, the weight and the response of said patient.
  • compositions can be prepared according to patent EP 526,348 B1 and US patent 5,338,755 or international application WO 98/24430.
  • Lactose monohydrate 344.40 mg Modified corn starch 60.77 mg

Abstract

The invention relates to the use of (2S)-1- [(2R,3S)-5- chloro-3-(2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy- 2,3-dihydro-1H-indole-2-carbonyl] pyrrolidine-2-carboxamide, the solvates thereof and/or pharmaceutically acceptable hydrates thereof in the production of medicaments used to treat or prevent Raynaud's phenomenon.

Description

UTILISATION DU (2S)-1-[(2R,3S)-5-CHLORO-3-(2-CHLOROPHENYL)-1- (3,4-DIMETHOXYBENZENESULFONYL)-3-HYDROXY-2,3-DIHYDRO- 1 H-INDOLE-2-CARBONYL] PYRROLIDINE-2-CARBOXAMIDE POUR LA PREPARATION DE MEDICAMENTS UTILES DANS LE TRAITEMENT DU PHENOMENE DE RAYNAUD.USE OF (2S) -1 - [(2R, 3S) -5-CHLORO-3- (2-CHLOROPHENYL) -1- (3,4-DIMETHOXYBENZENESULFONYL) -3-HYDROXY-2,3-DIHYDRO- 1 H- INDOLE-2-CARBONYL] PYRROLIDINE-2-CARBOXAMIDE FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OF RAYNAUD'S PHENOMENON.
La présente invention a pour objet une nouvelle utilisation d'un antagoniste sélectif des récepteurs V1a de l'arginine-vasopressine.The present invention relates to a new use of a selective antagonist of the V 1a receptors for arginine-vasopressin.
Le (2S)-1-[(2R, 3S)-5-chloro-3-(2-chlorophényl)-1-(3,4- diméthoxybenzènesulfonyI)-3-hydroxy-2,3-dihydro-1/- -indole-2- carbonyl]pyrrolidine-2-carboxamide, dont le nom de code est SR 49059, de formule :(2S) -1 - [(2R, 3S) -5-chloro-3- (2-chlorophenyl) -1- (3,4-dimethoxybenzenesulfonyI) -3-hydroxy-2,3-dihydro-1 / - - indole-2-carbonyl] pyrrolidine-2-carboxamide, whose code name is SR 49059, of formula:
Figure imgf000003_0001
ci-après dénommé composé A, a été décrit dans la littérature comme étant un antagoniste puissant et sélectif des récepteurs \ a de l'arginine- vasopressine chez différentes espèces, en particulier des récepteurs \ a humains, (C. Serradeil-Le Gai ét al., J. Clin. Invest., 1993, 92, 224-231 ). Il ne possède qu'une faible affinité pour les récepteurs V2. Le composé A est le plus puissant antagoniste sélectif des récepteurs V1a humains connu à ce jour. Les effets du composé A sur la vasoconstriction chez l'homme induite par injection d'arginine-vasopressine ont été décrits dans la littérature par R. Weber et al., Hypertension, 1997, 30(5), 1121-1127.
Figure imgf000003_0001
hereinafter referred to as compound A, was described in the literature as a potent and selective antagonist of \ a of arginine vasopressin in different species, particularly receptors \ a human, (C. Serradeil-Le Gay fl al., J. Clin. Invest., 1993, 92, 224-231). It has only a weak affinity for V 2 receptors. Compound A is the most potent selective human V 1a receptor antagonist known to date. The effects of compound A on vasoconstriction in humans induced by injection of arginine-vasopressin have been described in the literature by R. Weber et al., Hypertension, 1997, 30 (5), 1121-1127.
On a maintenant trouvé que le composé A, ainsi que ses solvats et/ou hydrates pharmaceutiquement acceptables, sont utiles dans le traitement ou la prévention du phénomène de Raynaud.It has now been found that compound A, as well as its pharmaceutically acceptable solvates and / or hydrates, are useful in the treatment or prevention of Raynaud's phenomenon.
Le phénomène de Raynaud comprend la maladie de Raynaud (primaire) et le syndrome de Raynaud (secondaire).Raynaud's phenomenon includes Raynaud's disease (primary) and Raynaud's syndrome (secondary).
Ainsi, selon un de ses aspects, la présente invention a pour objet l'utilisation du (2S)-1 -[(2R,3S)-5-chloro-3-(2-chlorophényl)-1 -(3,4- diméthoxybenzènesulfonyl)-3-hydroxy-2,3-dihydro-1 /-/-indole-2-carbonyl] pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la préparation de médicaments utiles dans le traitement ou la prévention du phénomène de Raynaud. En particulier, la présente invention a pour objet l'utilisation du (2S)-1-Thus, according to one of its aspects, the subject of the present invention is the use of (2S) -1 - [(2R, 3S) -5-chloro-3- (2-chlorophenyl) -1 - (3,4- dimethoxybenzenesulfonyl) -3-hydroxy-2,3-dihydro-1 / - / - indole-2-carbonyl] pyrrolidine-2-carboxamide, its pharmaceutically acceptable solvates and / or hydrates, for the preparation of medicaments useful in the treatment or prevention of Raynaud's phenomenon. In particular, the subject of the present invention is the use of (2S) -1-
[(2R,3S)-5-chloro-3-(2-chlorophényl)-1-(3,4-diméthoxybenzènesulfonyl)-3- hydroxy-2,3-dihydro-1 H-indole-2-carbonyl] pyrroIidine-2-carboxamide, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la préparation de médicaments utiles dans le traitement ou la prévention de la maladie de Raynaud.[(2R, 3S) -5-chloro-3- (2-chlorophenyl) -1- (3,4-dimethoxybenzenesulfonyl) -3- hydroxy-2,3-dihydro-1 H-indole-2-carbonyl] pyrroIidine- 2-carboxamide, of its pharmaceutically acceptable solvates and / or hydrates, for the preparation of medicaments useful in the treatment or prevention of Raynaud's disease.
En particulier aussi, la présente invention a pour objet l'utilisation du (2S)-1 -[(2R,3S)-5-chloro-3-(2-chlorophényl)-1 -(3,4- diméthoxybenzènesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl] pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la préparation de médicaments utiles dans le traitement ou la prévention du syndrome de Raynaud.Also in particular, the present invention relates to the use of (2S) -1 - [(2R, 3S) -5-chloro-3- (2-chlorophenyl) -1 - (3,4- dimethoxybenzenesulfonyl) -3 -hydroxy-2,3-dihydro-1H-indole-2-carbonyl] pyrrolidine-2-carboxamide, of its pharmaceutically acceptable solvates and / or hydrates, for the preparation of medicaments useful in the treatment or prevention of Raynaud's syndrome.
Selon un autre de ses aspects, la présente invention a pour objet une méthode de traitement ou de prévention du phénomène de Raynaud par administration d'une dose appropriée du composé A, de ses solvats et/ou hydrates pharmaceutiquement acceptables.According to another of its aspects, the subject of the present invention is a method of treatment or prevention of Raynaud's phenomenon by administration of an appropriate dose of compound A, of its pharmaceutically acceptable solvates and / or hydrates.
Le composé A, ses solvats et/ou hydrates, sont préparés selon le procédé décrit dans le brevet EP-526 348 B1 et dans le brevet US 5 338 755.Compound A, its solvates and / or hydrates, are prepared according to the process described in patent EP-526,348 B1 and in US patent 5,338,755.
Pour leur utilisation en tant que médicaments, le composé A et ses solvats et/ou hydrates pharmaceutiquement acceptables sont généralement administrés en unités de dosage. Lesdites unités de dosage sont de préférence formulées dans des compositions pharmaceutiques dans lesquelles le principe actif est mélangé avec un exipient pharmaceutique. Dans les compositions pharmaceutiques de la présente invention pour l'administration orale, sublinguale, inhalée, sous-cutanée, intramusculaire, intraveineuse, transdermique, locale ou rectale, le principe actif seul ou en association avec un autre principe actif peut être administré sous forme unitaire d'administration, en mélange avec des supports pharmaceutiques classiques, aux animaux et aux êtres humains. Les formes unitaires d'administration appropriées comprennent les formes par voie orale telles que les comprimés, les gélules, les poudres, les granules et les solutions ou suspensions orales, les formes d'administration sublinguale et buccale, les aérosols, les formes d'administration topiques, les implants, les formes d'administration sous-cutanée, transdermique, intramusculaire, intraveineuse, intranasale et les formes d'administration rectale.For their use as medicaments, compound A and its pharmaceutically acceptable solvates and / or hydrates are generally administered in dosage units. Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient. In the pharmaceutical compositions of the present invention for oral, sublingual, inhaled, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active ingredient alone or in combination with another active ingredient can be administered in unit form administration, mixed with conventional pharmaceutical carriers, animals and humans. Suitable unit administration forms include oral forms such as tablets, capsules, powders, granules and oral solutions or suspensions, sublingual and oral administration forms, aerosols, topical administration forms, implants, subcutaneous, transdermal, intramuscular, intravenous, intranasal and rectal administration forms.
Selon la présente invention, les formes orales d'administration sont préférées.According to the present invention, oral forms of administration are preferred.
Le dosage journalier du composé A est de 0,05 à 5 mg/kg, avantageusement de 1 à 2,5 mg/kg, préférentiellement de 2 à 2,5 mg/kg, à administrer en une ou plusieurs fois. Le composé A et ses solvats et/ou hydrates sont généralement formulés en unité de dosage contenant de 2,5 à 1000 mg, avantageusement de 2,5 à 500 mg, préférentiellement deThe daily dosage of compound A is from 0.05 to 5 mg / kg, advantageously from 1 to 2.5 mg / kg, preferably from 2 to 2.5 mg / kg, to be administered in one or more times. Compound A and its solvates and / or hydrates are generally formulated in dosage units containing from 2.5 to 1000 mg, advantageously from 2.5 to 500 mg, preferably from
2,5 à 250 mg, de principe actif par unité de dosage, à administrer une fois, deux fois ou plusieurs fois en même temps, selon la nécessité. Bien que ces dosages soient des exemples de situation moyennes, il peut y avoir des cas particuliers où des dosages plus élevés ou plus faibles sont appropriés, de tels dosages appartiennent également à l'invention. Selon la pratique habituelle, le dosage approprié à chaque patient est déterminé par le médecin selon le mode d'administration, l'âge, le poids et la réponse dudit patient.2.5 to 250 mg of active ingredient per dosage unit, to be administered once, twice or several times at the same time, as necessary. Although these dosages are examples of average situations, there may be special cases where higher or lower dosages are appropriate, such dosages also belong to the invention. According to usual practice, the appropriate dosage for each patient is determined by the doctor according to the mode of administration, the age, the weight and the response of said patient.
Les compositions pharmaceutiques peuvent être préparées selon le brevet EP 526 348 B1 et le brevet US 5 338 755 ou la demande internationale WO 98/24430.The pharmaceutical compositions can be prepared according to patent EP 526,348 B1 and US patent 5,338,755 or international application WO 98/24430.
Les effets du composé A ont été déterminés au cours d'une étude clinique réalisée en double aveugle, versus placebo, chez des patients âgés de 24 à 67 ans, présentant un phénomène de Raynaud primaire ou secondaire, en utilisant un test au froid, selon G. Bizzini Pezzetta et al.,The effects of compound A were determined during a double-blind, placebo-controlled clinical study in patients aged 24 to 67 with primary or secondary Raynaud's phenomenon, using a cold test, according to G. Bizzini Pezzetta et al.,
(Quantification of vasomotor altération in Raynaud's Phenomenon by digital plethysmography versus chronothermobiology in Proceedings of the 20th European Conférence on Microcirculation, Paris, France, August 30-September 2, 1998). Les patients ont reçu, par voie orale, une dose de 300 mg par jour de composé A, pendant une période de sept jours en plan croisé versus placebo, avec une période d'élimination de 21 jours. On a mesuré les effets sur la pression systolique digitale et la température digitale avant et après le test au froid. On a observé que le composé A, administré par voie orale pendant 7 jours, à des patients présentant un phénomène de Raynaud, montrait des effets positifs, comparé au placebo, sur la pression systolique digitale et le réchauffement digital. Les exemples suivants illustrent l'invention, sans toutefois la limiter. EXEMPLE 1 : Gélule dosée à 5 mg de composé A.(Quantification of vasomotor alteration in Raynaud's Phenomenon by digital plethysmography versus chronothermobiology in Proceedings of the 20 th European Conférence on Microcirculation, Paris, France, August 30-September 2, 1998). The patients received, orally, a dose of 300 mg per day of compound A, for a period of seven days in crossed plan versus placebo, with a elimination period of 21 days. The effects on digital systolic pressure and digital temperature were measured before and after the cold test. Compound A, administered orally for 7 days, to patients with Raynaud's phenomenon, has been observed to show positive effects, compared to placebo, on digital systolic pressure and digital warming. The following examples illustrate the invention without, however, limiting it. EXAMPLE 1 Capsule dosed at 5 mg of compound A.
Composé A micronisé 5,00 mgCompound A micronized 5.00 mg
Lactose monohydrate 344,40 mg Amidon de maïs modifié 60,77 mgLactose monohydrate 344.40 mg Modified corn starch 60.77 mg
Silice colloïdale anhydre 2,125 mgAnhydrous colloidal silica 2.125 mg
Stéarate de magnésium 4,25 mgMagnesium stearate 4.25 mg
Talc 8,50 mg Pour une gélule blanc opaque n° 0 remplie à 425 mg. EXEMPLE 2 : Gélule dosée à 25 mg de composé ATalc 8.50 mg For an opaque white capsule No. 0 filled to 425 mg. EXAMPLE 2 Capsule Dosed at 25 mg of Compound A
Composé A micronisé 25,00 mgMicronized Compound A 25.00 mg
Lactose monohydrate 327,40 mgLactose monohydrate 327.40 mg
Amidon de maïs modifié 57,77 mgModified corn starch 57.77 mg
Silice colloïdale anhydre 2,125 mg Stéarate de magnésium 4,25 mgColloidal anhydrous silica 2.125 mg Magnesium stearate 4.25 mg
Talc 8,50 mg Pour une gélule blanc opaque n° 0 remplie à 425 mg. EXEMPLE 3 : Gélule dosée à 100 mg de composé ATalc 8.50 mg For an opaque white capsule No. 0 filled to 425 mg. EXAMPLE 3 Capsule Dosed at 100 mg of Compound A
Composé A micronisé 100,00 mg Lactose monohydrate 263,60 mgCompound A micronized 100.00 mg Lactose monohydrate 263.60 mg
Amidon de maïs modifié 46,52 mgModified corn starch 46.52 mg
Silice colloïdale anhydre 2,125 mgAnhydrous colloidal silica 2.125 mg
Stéarate de magnésium 4,25 mgMagnesium stearate 4.25 mg
Talc 8,50 mg Pour une gélule blanc opaque n° 0 remplie à 425 mg. Talc 8.50 mg For an opaque white capsule No. 0 filled to 425 mg.

Claims

REVENDICATIONS
1. Utilisation du (2S)-1 -[(2R,3S)-5-chloro-3-(2-chlorophényl)-1 -(3,4- diméthoxybenzènesulfonyl)-3-hydroxy-2,3-dihydro-1 7-indole-2- carbonyl] pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la préparation de médicaments utiles dans le traitement ou la prévention du phénomène de Raynaud.1. Use of (2S) -1 - [(2R, 3S) -5-chloro-3- (2-chlorophenyl) -1 - (3,4- dimethoxybenzenesulfonyl) -3-hydroxy-2,3-dihydro-1 7-indole-2-carbonyl] pyrrolidine-2-carboxamide, of its pharmaceutically acceptable solvates and / or hydrates, for the preparation of medicaments useful in the treatment or prevention of Raynaud's phenomenon.
2. Utilisation selon la revendication 1 dans le traitement ou la prévention de la maladie de Raynaud.2. Use according to claim 1 in the treatment or prevention of Raynaud's disease.
3. Utilisation selon la revendication 1 dans le traitement ou la prévention du syndrome de Raynaud. 3. Use according to claim 1 in the treatment or prevention of Raynaud's syndrome.
PCT/FR2000/001085 1999-04-29 2000-04-25 Use of (2s)-1- [(2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h- indole-2-carbonyl] pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon WO2000066117A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43035/00A AU4303500A (en) 1999-04-29 2000-04-25 Use of (2s)-1- ((2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1(h)- indole-2-carbonyl) pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/05434 1999-04-29
FR9905434A FR2792834A1 (en) 1999-04-29 1999-04-29 USE OF SR 49059, ITS PHARMACEUTICALLY ACCEPTABLE SOLVATES AND / OR HYDATES FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF RAYNAUD PHENOMENON

Publications (1)

Publication Number Publication Date
WO2000066117A1 true WO2000066117A1 (en) 2000-11-09

Family

ID=9545016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/001085 WO2000066117A1 (en) 1999-04-29 2000-04-25 Use of (2s)-1- [(2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h- indole-2-carbonyl] pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon

Country Status (4)

Country Link
AR (1) AR023617A1 (en)
AU (1) AU4303500A (en)
FR (1) FR2792834A1 (en)
WO (1) WO2000066117A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526348A1 (en) * 1991-08-02 1993-02-03 Sanofi Indoline derivatives carrying an amide function, their preparation and pharmaceutical compositions containing them
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
WO1995018105A1 (en) * 1993-12-24 1995-07-06 Sanofi 1,3-dihydroindol-2-one derivatives substituted in position 3 by a nitrogen group as vasopressin and/or ocytocine agonists and/or antagonists
WO1999044613A1 (en) * 1998-03-06 1999-09-10 Sanofi-Synthelabo Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin v receptors, even of v1a and v2 receptors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
EP0526348A1 (en) * 1991-08-02 1993-02-03 Sanofi Indoline derivatives carrying an amide function, their preparation and pharmaceutical compositions containing them
WO1995018105A1 (en) * 1993-12-24 1995-07-06 Sanofi 1,3-dihydroindol-2-one derivatives substituted in position 3 by a nitrogen group as vasopressin and/or ocytocine agonists and/or antagonists
WO1999044613A1 (en) * 1998-03-06 1999-09-10 Sanofi-Synthelabo Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin v receptors, even of v1a and v2 receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"SR 49059", DATABASE PHAR (ONLINE) RETRIEVED FROM STN; AN=11309, XP002128619 *
C. SERRADEIL-LE GAL ET AL.: "Effects of SR 49059, a non-peptide antagonist of vasopressin V1a receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits", FUNDAMENTAL & CLINICAL PHARMACOLOGY, vol. 9, no. 1, 1995, pages 17 - 24, XP000866522 *
M. METZLER ET AL.: "Vasospastic disorders", POSTGRADUATE MEDICINE, vol. 65, no. 2, 1979, pages 79 - 88, XP000870196 *

Also Published As

Publication number Publication date
AU4303500A (en) 2000-11-17
AR023617A1 (en) 2002-09-04
FR2792834A1 (en) 2000-11-03

Similar Documents

Publication Publication Date Title
BE1005086A5 (en) Compositions for oral administration.
TW589174B (en) Agent for treating high-risk impaired glucose tolerance
EP1257275B1 (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
EP1221952B1 (en) Use of central cannabinoid receptor antagonist for preparing medicines
CH672068A5 (en)
CA2575059A1 (en) Pharmaceutical compositions comprising cilobradine
FR2735365A1 (en) USE OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURANE DERIVATIVE FOR THE PREPARATION OF A MEDICAMENT USEFUL IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS
FR2837706A1 (en) USE OF A CB1 CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF MEDICINES USEFUL FOR THE TREATMENT OF SEXUAL DYSFUNCTION AND / OR IMPROVING SEXUAL PERFORMANCE
EP1173179B1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent major depressive disorders
EP0429360B1 (en) Inhibition of withdrawal syndrome
HU205714B (en) Process for producing hypotensive pharmaceutical compositions by using combination of angiotensin converting enzyme inhibitors and potassium canal modulator
WO2000061125A2 (en) Osanetant in the treatment of mood disorders
WO2012077968A2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
FR2633831A1 (en) COMPOSITION COMPRISING A 5HT3 ANTAGONIST WITH A CYCLO-OXYGENASE INHIBITOR, METHOD FOR PRODUCING THE SAME, AND COMBINED USE OF A 5HT3 ANTAGONIST AND A THERAPEUTIC CYCLO-OXYGENASE INHIBITOR
CH678149A5 (en)
WO2000066117A1 (en) Use of (2s)-1- [(2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h- indole-2-carbonyl] pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon
JP4113257B2 (en) Use of cholinesterase inhibitors in the treatment of xerostomia
LU85242A1 (en) NEW DRUG ASSOCIATION
LU87033A1 (en) NEW DRUG ASSOCIATION
EP1115399B1 (en) Use of a pharmaceutical composition containing, in combination, an antagonist of the angiotensin ii at 1? receptors and indomethacin for making a medicine treating chronic glomerulonephritis
WO2023075461A1 (en) Composite composition containing angiotensin receptor blocker and sglt2 inhibitor
FR2641971A1 (en) ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION COMBINING BENAZEPRIL AND A THIAZIDE DIURETIC
EP2131842A2 (en) Use of a compound antagonist to the nk-2-receptors of a neurokinine for the preparation of drugs useful for preventing and treating sexual dysfunction
FR2846886A1 (en) Medicament for reducing risk of cardiovascular events, e.g. cardiac insufficiency, myocardial infarction or angina, in dialysis patients, containing fosinopril as active agent
EA003584B1 (en) A method for promoting smoking cessation or reduction or preventing relapse smoking and use of paroxetine or a pharmaceutically acceptable salt or solvate to produce a medicament

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP